Methyl-(1,3-dimethyl-hexyl)-amin | 15907-64-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Methyl-(1,3-dimethyl-hexyl)-amin
• 英文别名: N,4-dimethylheptan-2-amine
• CAS: 15907-64-9
• 化学式: C₉H₂₁N
• 分子量: 143.272
• InChiKey: MJLVRCDNTBVUHN-UHFFFAOYSA-N

物化性质

• 沸点：
  162.2±8.0 °C(predicted)
• 密度：
  0.767±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Methyl-(1,3-dimethyl-hexyl)-amin 、 3-溴丙炔 在 sodium carbonate 作用下， 以 苯 为溶剂， 生成 N,4-二甲基-N-(丙-2-炔-1-基)庚烷-2-胺
  参考文献：
  名称：

  Boissier,J.R. et al., Chimica Therapeutica, 1966, vol. 1, p. 320 - 326

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲基-2-庚酮 、 甲胺 生成 Methyl-(1,3-dimethyl-hexyl)-amin
  参考文献：
  名称：

  Boissier,J.R. et al., Chimica Therapeutica, 1966, vol. 1, p. 320 - 326

  摘要：

  DOI：

文献信息

• FGFR3 FUSION GENE AND PHARMACEUTICAL DRUG TARGETING SAME
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP2902489A1

  公开（公告）日：2015-08-05

  In the present invention, as a result of detailed research into the expression, over-amplification, mutation and translocation, and the like of FGFR coding genes in a variety of cancer cells, a novel fusion polypeptide obtained by fusion of FGFR3 polypeptide with another polypeptide was identified and isolated in multiple urinary bladder cancer-derived cells and lung cancer cells. By using this fusion polypeptide as a biomarker in cancer therapy with an FGFR inhibitor, it is possible to preemptively prevent the manifestation of side effects in therapy with an FGFR inhibitor and control the therapeutic mode such that the best possible therapeutic results are obtained, and individualized medical treatment is possible.

  在本发明中，通过对多种癌细胞中表皮生长因子受体编码基因的表达、过度扩增、突变和易位等进行详细研究，在多种膀胱癌衍生细胞和肺癌细胞中发现并分离出了一种新型融合多肽，该多肽由表皮生长因子受体 3 多肽与另一种多肽融合而成。在使用表皮生长因子受体抑制剂进行癌症治疗时，将这种融合多肽作为生物标记物，可以预先防止表皮生长因子受体抑制剂在治疗过程中产生副作用，并控制治疗模式，从而获得最佳治疗效果，实现个体化治疗。
• ELECTRICAL DETECTION PROCESS FOR PEPTIDES, PROTEINS AND OTHER MACROMOLECULES
  申请人：EXCILONE

  公开号：US20190317006A1

  公开（公告）日：2019-10-17

  An aerolysin nanopore or a nanotube is used for the electrical detection of peptides, proteins separated by at least one amino acid and other macromolecules such as polysaccharides or synthetic or natural polymers present in a preparation where said nanopore or nanotube is inserted into a lipid membrane which is subjected to a difference in potential greater than −160 mV, in a reaction medium having an alkali metal halide electrolyte solution with a concentration of less than 6M and at a temperature of less than 40° C., and where said use is intended to differentiate said peptides, proteins and other molecules according to their length and their mass. Application to the sequencing of peptides and other molecules to differentiate them according to their length and mass with an amino acid-level or monomer-level resolution and to medical diagnosis.
• US9833150B2
  申请人：——

  公开号：US9833150B2

  公开（公告）日：2017-12-05
• Boissier,J.R. et al., Chimica Therapeutica, 1966, vol. 1, p. 320 - 326
  作者：Boissier,J.R. et al.

  DOI：——

  日期：——